# Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors

> **NCT06878664** · PHASE3 · RECRUITING · sponsor: **Grupo Espanol de Tumores Neuroendocrinos** · enrollment: 166 (estimated)

## Conditions studied

- Grade1-2 Advanced Midgut Neuroendocrine Tumors (NETs)

## Interventions

- **DRUG:** 177Lu-Dotatate (7.4 Gigabecquerel/cycle) during 30 min intravenous infusion every 16 weeks (q8w) x 4 cycles; 2) and 3) as in the experimental arm.
- **DRUG:** 177Lu-Dotatate (7.4 Gigabecquerel/cycle) during 30 min intravenous infusion every 8 weeks (q8w) x 4 cycles; 2) and 3) as in the experimental arm.
- **DRUG:** Amino acid solution
- **DRUG:** Lanreotide (Autogel formulation) or Octreotide LAR

## Key facts

- **NCT ID:** NCT06878664
- **Lead sponsor:** Grupo Espanol de Tumores Neuroendocrinos
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-12
- **Primary completion:** 2029-01
- **Final completion:** 2029-01
- **Target enrollment:** 166 (ESTIMATED)
- **Last updated:** 2025-09-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06878664

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06878664, "Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06878664. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*